Idioma:

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Ryan, Charles J ; Smith, Matthew R ; de Bono, Johann S ; Molina, Arturo ; Logothetis, Christopher J ; de Souza, Paul ; Fizazi, Karim ; Mainwaring, Paul ; Piulats, Josep M ; Ng, Siobhan ; Carles, Joan ; Mulders, Peter F.A ; Basch, Ethan ; Small, Eric J ; Saad, Fred ; Schrijvers, Dirk ; Van Poppel, Hendrik ; Mukherjee, Som D ; Suttmann, Henrik ; Gerritsen, Winald R ; Flaig, Thomas W ; George, Daniel J ; Yu, Evan Y ; Efstathiou, Eleni ; Pantuck, Allan ; Winquist, Eric ; Higano, Celestia S ; Taplin, Mary-Ellen ; Park, Youn ; Kheoh, Thian ; Griffin, Thomas ; Scher, Howard I ; Rathkopf, Dana E

The New England journal of medicine, 2013-01, Vol.368 (2), p.138-148 [Periódico revisado por pares]

Waltham, MA: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Autor: Ryan, Charles J ; Smith, Matthew R ; de Bono, Johann S ; Molina, Arturo ; Logothetis, Christopher J ; de Souza, Paul ; Fizazi, Karim ; Mainwaring, Paul ; Piulats, Josep M ; Ng, Siobhan ; Carles, Joan ; Mulders, Peter F.A ; Basch, Ethan ; Small, Eric J ; Saad, Fred ; Schrijvers, Dirk ; Van Poppel, Hendrik ; Mukherjee, Som D ; Suttmann, Henrik ; Gerritsen, Winald R ; Flaig, Thomas W ; George, Daniel J ; Yu, Evan Y ; Efstathiou, Eleni ; Pantuck, Allan ; Winquist, Eric ; Higano, Celestia S ; Taplin, Mary-Ellen ; Park, Youn ; Kheoh, Thian ; Griffin, Thomas ; Scher, Howard I ; Rathkopf, Dana E
Assuntos: Abiraterone Acetate ; Androstadienes - adverse effects ; Androstadienes - therapeutic use ; Antineoplastic Agents, Hormonal - adverse effects ; Antineoplastic Agents, Hormonal - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Clinical trials ; Disease-Free Survival ; Dose-response relationship (Biochemistry) ; Double-Blind Method ; Drug therapy ; Drugs ; General aspects ; Humans ; Male ; Medical sciences ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasm Metastasis ; Nephrology. Urinary tract diseases ; Patient outcomes ; Prednisone - adverse effects ; Prednisone - therapeutic use ; Product/Service Evaluations ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - secondary ; Regulatory approval ; Survival Analysis ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland
É parte de: The New England journal of medicine, 2013-01, Vol.368 (2), p.138-148
Descrição: Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant improvement in progression-free survival with abiraterone as first-line chemotherapy in these patients. Metastatic castration-resistant prostate cancer, defined by tumor growth despite a testosterone level of less than 50 ng per deciliter (1.7 nmol per liter), causes approximately 258,400 deaths annually worldwide. 1 , 2 Death of patients with this condition, which typically occurs within 24 to 48 months after the onset of castration resistance, is commonly preceded by a sequence of landmark events associated with deterioration of overall health and worsening symptoms (Figure S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). 3 – 7 Among the treatment options for patients with metastatic castration-resistant prostate cancer who have not undergone chemotherapy . . .
Editor: Waltham, MA: Massachusetts Medical Society
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 5 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Waltham, MA: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.